X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

GSK Unveils Its Transformation Through New Branding And Logo

Content Team by Content Team
13th June 2022
in Manufacturing, Middle East and South Asia, News
GSK Unveils Its Transformation Through New Branding And Logo

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The British Big Pharma has launched an innovative rebranding, a tech-flavoured logo, and an impactful transformation for the future as GlaxoSmithKline turns GSK and eliminates its consumer unit. GSK has utilised the orange colour in its logo for a long time, and it continues to do so with the trimmed down GSK trademark, albeit in a darker shade than before. The colour scheme has also been reversed– instead of white letters on an orange background, the text is now orange with no base colour.

The GSK is now all capital and stands alone, making for a more powerful logo than the previous one, which employed lowercase text enclosed in an oval shape for a softer appeal. A GSK spokeswoman confirmed that their name and the unique colour both happen to be key parts of their identity and will remain an important part of the new brand.

According to the spokesperson, the new design was inspired by catching image found in biosciences, and it features numerous curving forms that evoke the agile and adaptable aspects of the human immune system, serving as a message of the continuous need to develop and adjust. This also reflects GSK’s research and development goals, which are focused on harnessing the body’s immune system to help develop new and better medications.

The dynamic and innovative GSK logo, housed in a revamped shape known as the signal, consistently marks the way ahead, GSK noted. The identity system flexes, adapts, and moves to engage audiences in all of the brand’s digital, social, and physical settings.

This comes as the company prepares to spin off its consumer division, Haleon, which will be the largest company to float on the London Stock Exchange in more than a decade. GSK is expected to become a slimmer, meaner R & D engine as the demerger process gets going in the coming weeks, and the shift in branding and logos reflects this broader change within the company.

Following the demerger, GSK will be entirely focused on biopharmaceutical innovation, with a new purpose to bring science, technology, and talent together to move ahead of disease, the drugmaker added. This new purpose and expansion objectives are reflected in their branding. It draws together science, technology, and skills while also conserving vital aspects of history. The redesign comes a month after GlaxoSmithKline dropped GlaxoSmithKline as its official name in favour of GSK. These changes mark the end of a 20-year trademark that began with the merger of Glaxo Wellcome and SmithKline Beecham to form GlaxoSmithKline at the turn of the millennium.

The drugmaker still wants its history to be a part of the company, but the new logo reflects its desire for collaborative partnerships. This will extend to how the new GSK communicates with the media, with a focus on straightforward language. Sanofi, a French pharmaceutical company, made a similar switch at the start of the year, dropping the Pasteur and Genzyme names and rebranding as just Sanofi. With the switch came a new, streamlined logo that included a homage to the tech sector.

Previous Post

Vazkepa From Amarin Gets Recommended By NICE In The U.K

Next Post

ACHEMA 2022 addresses the industry's key issues digitalisation and sustainability

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
ACHEMA 2022 addresses the industry's key issues digitalisation and sustainability

ACHEMA 2022 addresses the industry's key issues digitalisation and sustainability

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In